| Liposomes Useful for Drug Delivery |
2022-11-17 |
2023-6-15 |
|
| Stabilizing Camptothecin Pharmaceutical Compositions |
2022-8-31 |
2023-4-06 |
|
| Methods For Treating Pancreatic Cancer Using Combination Therapies |
2022-5-25 |
2023-3-23 |
|
| Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies … |
2022-4-01 |
2023-3-02 |
|
| Combination Therapy for Cancer Treatment |
2022-3-24 |
2023-3-09 |
|
| Nanoliposomal Irinotecan for Use in Treating Small Cell Lung Cancer |
2022-3-21 |
2023-1-05 |
|
| Inhibiting ataxia telangiectasia and rad3-related protein (atr) |
2021-7-21 |
2021-11-11 |
|
| Antibodies against the ectodomain of erbb3 and uses thereof |
2021-7-15 |
2022-6-30 |
|
| Bi-Specific Fusion Proteins |
2021-3-25 |
2021-7-15 |
|
| Stabilizing Camptothecin Pharmaceutical Compositions |
2021-3-22 |
2021-7-08 |
|
| Methods For Treating Pancreatic Cancer Using Combination Therapies Comprising … |
2021-3-17 |
2022-3-31 |
|
| Anti-tnfr2 antibodies and uses thereof |
2020-2-28 |
2022-1-05 |
|
| Treatment of Breast Cancer with Liposomal Irinotecan |
2019-12-11 |
2020-11-19 |
|
| Anti-TNFR2 antibodies and uses thereof |
2019-9-18 |
2021-7-15 |
|
| Ephrin receptor a2 (epha2)-targeted docetaxel-generating nano-liposome … |
2018-8-21 |
2018-10-31 |
|
| Engineered trail for cancer therapy |
2018-8-21 |
2018-10-31 |
|
| Methods of treating patients having mutations in the extracellular domain of … |
2018-8-08 |
2019-1-11 |
|
| Combination treatments with seribantumab |
2018-8-02 |
2019-1-11 |
|
| Methods for treating er , her2-, hrg breast cancer using combination therapies … |
2018-8-01 |
2018-10-31 |
|
| Compositions and methods for delivering nucleic acid to a cell |
2018-7-02 |
2019-1-17 |
|
| Use of erbb3 inhibitors in the treatment of triple negative and basal-like … |
2018-5-31 |
2019-4-25 |
|
| 4-1bb agonist and cd40 agonist bispecific molecules |
2018-5-18 |
2018-11-22 |
|
| Bispecific 4-1bb agonist molecules |
2018-4-02 |
2018-10-11 |
|
| Epha2-targeted docetaxel -generating liposomes in combination with an agent … |
2018-3-01 |
2018-9-07 |
|
| Tnf superfamily fusion polypeptides |
2018-1-31 |
2018-8-09 |
|
| Anti-fgfr antibodies and methods of use |
2018-1-08 |
2018-8-09 |
|
| ANTI-FGFR ANTIBODIES (FIBROBLAST GROWTH FACTOR RECEIVER) AND METHODS OF USE |
2018-1-08 |
2019-5-08 |
|
| Antibodies against epidermal growth factor receptor (egfr) and uses thereof |
2017-11-21 |
2018-5-10 |
|
| Treating gastric cancer using combination therapies comprising liposomal … |
2017-11-01 |
2021-7-27 |
2021-7-27 |
| Combination of an erbb3 inhibitor, topoisomerase i inhibitor, and an alkylating … |
2017-9-01 |
2018-3-08 |
|
| Monospecific and bispecific anti-IGF-IR and anti-ErbB3 antibodies |
2017-8-16 |
2017-8-31 |
|
| Heteromeric polypeptides |
2017-8-02 |
2018-7-12 |
|
| Antibodies against epidermal growth factor receptor (egfr) and uses thereof |
2017-6-22 |
2017-11-02 |
|
| Combination therapies comprising anti-erbb3 agents |
2017-6-22 |
2018-3-08 |
|
| Non-Invasive Imaging Methods for Patient Selection for Treatment with … |
2017-6-14 |
2017-11-30 |
|
| Methods for selecting and treating patients with a trail-based therapeutic or … |
2017-6-13 |
2020-2-26 |
|
| Biomarker profiles for predicting outcomes of cancer therapy with erbb3 … |
2017-5-22 |
2017-9-21 |
|
| Combination therapies for treating her2-positive cancers that are resistant to … |
2017-5-18 |
2017-9-14 |
|
| Population Pharmacokinetics of Liposomal Irinotecan |
2017-5-18 |
2017-11-23 |
|
| Dosage and administration of monospecific and bispecific anti-igr-1r and anti- … |
2017-5-17 |
2018-2-08 |
|
| Dosage and administration of anti-egfr therapeutics |
2017-5-17 |
2017-9-07 |
|
| Nanoliposomal irinotecan for use in treating small cell lung cancer |
2017-5-17 |
2022-5-03 |
2022-5-03 |
| Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, … |
2017-4-14 |
2017-10-19 |
|
| Methods for treating cancer using combination therapies comprising an … |
2017-3-28 |
2017-10-05 |
|
| Dosage and administration for preventing cardiotoxicity in treatment with erbb2 … |
2017-3-23 |
2017-6-01 |
|
| Treating Ephrin Receptor A2 (Epha2) Positive Cancer with Targeted Docetaxel- … |
2017-3-16 |
2019-3-07 |
|
| COMPOSITIONS OF DOCETAXEL GENERATING NANOLIPOSOMES DIRECTED TO THE EFRINE A2 … |
2017-3-16 |
2018-6-28 |
|
| Nanoliposomal Targeting of Ephrin Receptor A2 (Epha2) and Related Diagnostics |
2017-3-16 |
2019-10-03 |
|
| Dosage and administration of combination therapies comprising targeted … |
2017-3-15 |
2017-9-21 |
|
| Protein A binding polypeptides, anti-EphA2 antibodies and methods of use … |
2017-3-15 |
2017-11-01 |
|
| PROTEIN A BINDING POLIPEPTIDES, ANTI-EPHA2 ANTIBODIES AND METHODS OF USE OF … |
2017-3-15 |
2018-6-13 |
|
| Treatment of her2-intermediate cancer |
2017-2-03 |
2017-8-10 |
|
| Dosage and administration of combination therapies comprising istiratumab, uses … |
2017-1-19 |
2017-8-17 |
|
| Inhibiting b-cell lymphoma 2 (bcl-2) and related proteins |
2017-1-11 |
2017-7-20 |
|
| Treatment of pancreatic cancer with liposomal irinotecan |
2017-1-11 |
2017-7-20 |
|
| Cartilage-binding fusion proteins |
2017-1-05 |
2017-11-16 |
|
| Methods, systems and products for predicting response of tumor cells to a … |
2016-12-20 |
2017-10-26 |
|
| Tandem fc bispecific antibodies |
2016-12-09 |
2017-8-03 |
|
| Treatment of Breast Cancer with Liposomal Irinotecan |
2016-12-09 |
2017-6-01 |
|
| Bispecific binding agents targeting the igf-1r and erbb3 pathways and uses … |
2016-12-07 |
2017-7-27 |
|
| Marker quantitation in single cells in tissue sections |
2016-12-06 |
2017-3-23 |
|
| Disulfide-stabilized fabs |
2016-12-05 |
2018-9-27 |
|
| Combination Therapies for Treating Her2-Positive Cancers that are Resistant to … |
2016-12-05 |
2017-3-23 |
|
| Methods and compositions for improving outcomes of liposomal chemotherapy |
2016-11-21 |
2017-8-17 |
|
| Compositions and methods for non-invasive imaging |
2016-11-01 |
2018-5-15 |
2018-5-15 |
| Methods of treating cancer by administering a mek inhibitor and a combination … |
2016-10-21 |
2017-4-27 |
|
| Methods of treating cancer by administering a bispecific antibody antagonist of … |
2016-10-21 |
2017-4-27 |
|
| DOSAGE AND ADMINISTRATION OF ANTI-c-MET, ANTI-EpCAM BISPECIFIC ANTIBODIES, USES … |
2016-10-20 |
2017-4-27 |
|
| Liposomes Useful for Drug Delivery to the Brain |
2016-10-18 |
2017-2-09 |
|
| Anti-c-met tandem fc bispecific antibodies |
2016-9-30 |
2017-3-23 |
|
| Human serum albumin linkers and conjugates thereof |
2016-8-30 |
2017-7-20 |
|
| Combination therapies for treatment of heregulin positive cancers |
2016-8-26 |
2017-3-02 |
|
| Treatment of pancreatic cancer with liposomal IRINOTECAN |
2016-8-19 |
2017-5-16 |
|
| DOSAGE AND ADMINISTRATION OF ANTI-IGF-1R, ANTI-ErbB3 BISPECIFIC ANTIBODIES, … |
2016-8-19 |
2017-4-06 |
|
| DOSAGE AND ADMINISTRATION OF ANTI-c-MET, ANTI-EpCAM BISPECIFIC ANTIBODIES, USES … |
2016-6-22 |
2016-12-29 |
|
| Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
2016-6-03 |
2019-1-22 |
2019-1-22 |
| Combination therapies for treating her2-positive cancers |
2016-5-31 |
2017-1-26 |
|
| Combination cancer therapies |
2016-5-27 |
2017-12-07 |
|
| Liposomes useful for drug delivery |
2016-5-23 |
2016-6-16 |
|
| Compositions for improving the pharmacokinetics and therapeutic index of cancer … |
2016-4-14 |
2016-10-20 |
|
| Combination therapy for treating her2-positive cancers her-2 |
2016-3-14 |
2016-8-12 |
|
| Predicting tumor responses to antibodies against hepatocyte growth factor (hgf) … |
2015-10-01 |
2017-10-26 |
|
| Antibodies against epidermal growth factor receptor (egfr) and uses thereof |
2015-9-08 |
2015-12-24 |
|
| Methods for selecting therapeutics for treatment of her2+ cancers |
2015-6-11 |
2015-12-17 |
|
| Dosage and administration of bispecific scfv conjugates in combination with … |
2014-11-09 |
2015-1-29 |
|
| Human serum albumin linkers and conjugates thereof |
2014-10-23 |
2015-3-26 |
|
| Liposomes for non-invasive imaging and drug delivery |
2014-10-23 |
2015-4-30 |
|
| Compositions and methods for treating osteolytic bone disorders |
2014-3-28 |
2014-10-02 |
|
| Anti-erbb3 antibodies in combination with paclitaxel for the treatment of … |
2014-1-29 |
2014-2-10 |
|
| Pharmaceutical combination comprising an anti-erbb3 antibody and paclitaxel; |
2013-12-30 |
2014-7-25 |
|
| Methods for preventing toxic drug-drug interactions in combination therapies … |
2013-10-24 |
2013-12-31 |
|
| Overcoming resistance to erbb pathway inhibitors |
2013-9-12 |
2013-12-31 |
|
| Combination therapies comprising anti-erbb3 agents |
2013-8-22 |
2013-9-30 |
|
| Bi-specific fusion proteins |
2013-4-03 |
2013-5-02 |
|
| Methods for treating pancreatic cancer using combination therapies comprising … |
2013-3-12 |
2013-9-19 |
|
| Bispecific binding agents for modulating biological activity |
2013-2-22 |
2013-7-18 |
|
| Treatment of advanced solid tumors using combination of anti-ErbB3 … |
2012-8-09 |
2013-3-21 |
|
| DOSAGE AND ADMINISTRATION OF ANTI-ERBB3 ANTIBODIES IN COMBINATION WITH … |
2012-6-22 |
2013-1-31 |
|
| DOSAGE AND ADMINISTRATION OF ANTI-ERBB3 ANTIBODIES IN COMBINATION WITH … |
2012-6-15 |
2013-1-31 |
|
| Methods and kits for predicting tumor responses to antibodies against epidermal … |
2012-6-06 |
2012-12-05 |
|